

Docket No.: B45326

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"IMMUNOGENIC COMPOSITION"

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 30 October 2003 Serial No. PCT/EP2003/012160
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.


I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s) Number	Country	Filing Date	Priority Claimed
0225543.8	GB	01-Nov-2002	YES
0225520.6	GB	01-Nov-2002	YES
0225532.1	GB	01-Nov-2002	YES
0317381.2	GB	24-Jul-2003	YES
0317380.4	GB	24-Jul-2003	YES
0317371.3	GB	24-Jul-2003	YES

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37,



10/533464

03/03/2006 14:48 6102705090

GLAXOSMITHKLINE

PAGE 03/08

Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

Direct all correspondence to the address associated with Customer Number 20462.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Yves MAYERESSE

Inventor's Signature: 

Date: 22 April 2005


Residence: Rixensart, Belgium

Citizenship: Belgian

BEX

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Jean STEPHENNE

Inventor's Signature: 

Date: 25 April 2005

Residence: Rixensart, Belgium

Citizenship: Belgian

BEX

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

BEST AVAILABLE COPY

BEST AVAILABLE COPY

Rec'd PCT/PTO 03 MAR 2006

10/533464

03/03/2006 14:48 6102705090

GLAXOSMITHKLINE


PAGE 05/08

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: GlaxoSmithKline Biologicals s.a. International Application No./Patent No.: <u>PCT/EP2003/012160</u> Filed/Issue Date: 30 October 2003 Entitled: <u>IMMUNOGENIC COMPOSITION</u>	
GlaxoSmithKline Biologicals s.a., a corporation, states that it is:	
1. <input checked="" type="checkbox"/> the assignee of the entire right, title, and interest; or	
2. <input type="checkbox"/> an assignee of less than the entire right, title and interest. The extent (by percent age) of its ownership interest is _____ % in the patent application/patent identified above by virtue of either;	
A. <input type="checkbox"/> An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which copy thereof is attached.	
OR	
B. <input type="checkbox"/> A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:	
1. From: _____ To: _____ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.	
2. From: _____ To: _____ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.	
3. From: _____ To: _____ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.	
<input type="checkbox"/> Additional documents in the chain of title are listed on a supplemental sheet.	
<input checked="" type="checkbox"/> Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.	
 Signature	09 MAY 2005 Date
Marcus Jonathan William DALTON Printed or Typed Name	+44 20 8047 4401 Telephone Number
Attorney and Authorized Official Title	

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

03/03/2006 14:48 6102705090

GLAXOSMITHKLINE

PAGE 06/08

Docket No.: B45326

Rec'd PCT/PTO 03 MAR 2006

ASSIGNMENT

10/533 464

WHEREAS I/We, Yves MAYERESSE and Jean STEPHENNE both of Rixensart, Belgium have made an invention entitled:


IMMUNOGENIC COMPOSITION

for which on April 22 & 25, 2005 I/we executed an application for Letters Patent of the United States of America;


NOW, THEREFORE, in return for valuable consideration paid to me/us by GlaxoSmithKline Biologicals s.a. of Rue de l'Institut 89, B-1330 Rixensart, Belgium (hereinafter "ASSIGNEE"), the receipt of which is hereby acknowledged and intending to be legally bound, I/we do hereby assign unto the said ASSIGNEE, its successors and assigns, the entire right, title and interest in and to the said invention, said executed application, any division, continuation and continuation-in-part of said application and reissue applications, and all Letters Patents of the United States of America to be obtained therefor;

I/we hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale;

In addition I/we agree to provide ASSIGNEE upon its request with all pertinent facts and documents relating to said invention, and said Letters Patent as may be known and accessible to me/us, and to testify as to the same in any interference or litigation related thereto, and to execute further instruments (including divisional, continuation, continuation-in-part or reissue applications, affidavits or other instruments) required to apply for, obtain, maintain and enforce said application and said Letters Patent which may be necessary; this agreement to be binding upon my/our heirs, executors and administrators.


Inventor 1
Yves MAYERESSE

Date: 22 April 2005


Inventor 2
Jean STEPHENNE

Date: 25 April 2005

BEST AVAILABLE COPY

Rec'd PCT/PTO

03 MAR 2006

10/533464

03/03/2006 14:48

6102705090

GLAXOSMITHKLINE

PAGE 04/08

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number	PCT/EP2003/012160
	Filing Date	30 October 2003
	First Named Inventor	Yves MAYERESSE
	Title	IMMUNOGENIC COMPOSITION
	Art Unit	
	Examiner Name	
	Attorney Docket Number	B45326
I hereby appoint: <input checked="" type="checkbox"/> Practitioners associated with the Customer Numbers. 20462 Or <input type="checkbox"/> Practitioner(s) named below:		
Name		Registration Number
As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.		
Please recognize or change the correspondence address for the above-identified application to: <input type="checkbox"/> The address associated with the above-mentioned Customer Number: Or <input checked="" type="checkbox"/> The address associated with Customer Number 20462 Or <input type="checkbox"/> Firm or Individual Name:		
Address:		
Address:		
City:		State: Zip:
Country:		
Telephone:		Fax:
I am the: <input type="checkbox"/> Applicant/Inventor: <input checked="" type="checkbox"/> Assignee or record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)		
SIGNATURE of Applicant or Assignee of Record		
Signature: <i>Marcus Jonathan William Dalton</i>		Date: 09 MAY 2005
Name: Marcus Jonathan William DALTON		Telephone: +44 20 8047 4401
Title and Company: Attorney and Authorised Official, GlaxoSmithKline Biologicals s.a.		
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.		
<input type="checkbox"/> *Total of: forms are submitted.		

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.